www.standoutstocks.com: Stocks That Stand Out For Nov. 17th, 2009 Are HLXW, BRGO, NYMH, ACTC, GOVX

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com

_________________________________________________

Helix Wind's S322 Turbine Helps Power School on Island of Malta

Second S322 unit to be installed by the Maltese Government this month

SAN DIEGO, Nov 17, 2009 -- Helix Wind Corp. (OTCBB: HLXW), a global renewable energy company, announced today that a model S322 wind turbine has withstood gale-force winds after being installed on a primary school on Malta, an island located in the Mediterranean Sea between Italy and Africa. Installed in September on the Pembroke Primary School, the turbine is part of a six-month test, which, if successful, could result in the installation of S322 turbines atop 40 other schools on the island.

In addition, Helix Wind announced it is installing another S322 on Malta to power a center at a government-owned plastics recycling plant. The S322 was chosen particularly for its superior low-noise performance, since the existing horizontal wind turbine from another manufacturer was causing unsatisfactory levels of noise pollution. The installation is part of the Maltese Government's dedication to fostering wind energy projects that reduce energy costs and pollution on the island.

"Helix Wind's quiet, scalable and beautiful wind turbines are going global," said Scott Weinbrandt, chairman and president of Helix Wind. "In addition to these units on Malta, Helix Wind is currently delivering turbines for installation in Sweden, Ireland, France and Italy." The Pembroke Primary opened in September as part of the Maltese Government program called Foundation of Tomorrow Schools, which funds alternative, efficient and cost-effective approaches to developing and upgrading Maltese schools. To see a video of the Helix turbine in action at the school, visit: http://www.youtube.com/watch?v=t0GrIhz0oWo.

Godfrey Formosa, managing director of environmental consultant and Helix Wind distributor Di Natura, said, "The 322 has already shown it can stand up to Malta's gale-force winds and we are looking forward to participating in the Maltese government's farsighted vision to capitalize on the island's wind resources. At Di Natura, our motto is 'Think Beyond'. We believe the future is now, and our lives will depend on it. More importantly the lives of our children, and their children, will be dependent on the choices we make today." About Helix: Helix Wind Corp., a global renewable energy company, is engaged in the design, manufacturing and sale of small wind vertical axis turbine designed to generate 300W, 1kW, 2.0kW, 4.0kW, and 50kW of clean, renewable electricity. Additional information can be found at http://www.helixwind.com.

About Di Natura: Di Natura has made a commitment to reconcile commercial objectives with a strong statement on preserving the environment. We feel it is within our power to make a difference, and we exercise this right by promoting products and solutions that take the most advantage of the laws of nature and contribute positively to long-term sustainable development. Our aim is to contribute to human progress by seeking products that strike a fair balance between global access to heat, light, wind and water while reducing waste, emissions and discharges, thereby protecting and improving the natural environment Safe Harbor Statement: A number of statements contained in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including our ability to attract and retain management and field personnel with experience in the small wind turbine industry, our ability to raise capital when needed and on acceptable terms and conditions, the intensity of competition and general economic factors. The actual results Helix Wind may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. Helix Wind encourages the public to read the information provided here in conjunction with its most recent filings, which may be viewed at www.sec.gov.

Bergio International Goes Public

FAIRFIELD, N.J., Nov 17, 2009 -- Bergio International, Inc. (OTC Bulletin Board: BRGO) announced today that the company has gone public and started trading on the "Over The Counter Bulletin Boards." "We are very excited to take Bergio to the next level in its corporate growth. Going public will help us in our process of marketing Bergio to the world," stated Berge Abajian, CEO of Bergio International, Inc.

About Bergio International, Inc.

Bergio is a entering into our 20th year of operations and concentrates on boutique, upscale jewelry stores. It currently sells its jewelry to approximately 150 independent jewelry retailers across the United States. Bergio has spent millions in branding the Bergio brand through tradeshows, trade advertising, national advertising and billboard advertising since launching the line in 1995. Bergio has manufacturing control over our line as a result of having a manufacturing facility in New Jersey as well as subcontracts with facilities in Italy and Bangkok.

We have establish Bergio International as a holding company for the purpose of acquiring established jewelry design and manufacturing firms who possess branded product lines.

Additionally, Bergio intends to acquire design and manufacturing firms throughout the United States and Europe. If and when we pursue any potential acquisition candidates, we intend to target the top 10% of the world's jewelry manufactures that have already created an identity and brand in the jewelry industry.

Forward-Looking Statement: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from acquisitions or actions in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those contained in such statements. Such risks, uncertainties, and factors include, but are not limited to, future capital needs, changes, and delays in product development plans and schedules, or market acceptance.

NYMET Holdings Inc. (NYMH) Announces Credit Line Approval

NEW YORK, NY, Nov 16, 2009 -- NYMET Holdings Inc. (PINKSHEETS: NYMH | Quote | Chart | News | PowerRating) (www.nymetholdings.com), an innovative metals and mining company headquartered in Port Jefferson, N.Y., announced today that NYMET Holdings Inc. has obtained a credit line approval from a New York based factor and finance company.

The $900,000 credit line was approved as part of a working agreement for projects and material purchases associated with NYMET Holdings Inc. and its subsidiaries.

The credit line provides NYMET with funds to expand its revenue stream, as well as execute the company's current business development plan which has been formulated by management. Additionally, this approval allows NYMET the ability to factor its Letters of Credit, which NYMET will receive from clients overseas.

DISCLAIMER: CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS The results described herein cannot be guaranteed. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release other than statements of historical fact are "forward-looking statements" that are based on current expectations and assumptions. These expectations and assumptions are subject to risks and uncertainty, which could affect NYMET Holdings Inc.'s future. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the statements, including, but not limited to, the following: the ability of NYMET Holdings Inc. to provide for its obligations, to provide working capital needs from operating revenues, to obtain additional financing needed for any future acquisitions, to meet competitive challenges and technological changes, and other risks. NYMET Holdings Inc. undertakes no duty to update any forward-looking statement(s) and/or to confirm the statement(s) to actual results or changes in NYMET Holdings Inc.'s expectations.

Advanced Cell Technologies Strengthens Balance Sheet Through Completion of Private Placements

Funding to Be Used to Accelerate RPE Program and Expand Clinical Development Activities

WORCESTER, Mass., Nov 16, 2009 -- Advanced Cell Technology, Inc. ("Advanced Cell", or the "Company") (OTCBB: ACTC), announced today that it has entered into definitive agreements on three private placements with institutional and other accredited investors under which the Company has received definitive commitments in excess of $15 million. The three investments are expected to provide proceeds sufficient to fund the Company's general operations and working capital for the next two years. Much of the proceeds will be used to support the Company's Retinal Pigment Epithelial (RPE) program, which the Company expects to commence later this year through the filing of an IND with the FDA, in addition to funding development of certain other pre clinical programs.

"We are extremely pleased to have negotiated these financings, with the support of existing debt holders, which will leave us sufficiently capitalized well into 2011," remarked William M. Caldwell IV, CEO of Advanced Cell. "In addition to satisfying our operational and working capital needs, these funds will be integral in advancing our RPE Program through the clinic once we receive FDA clearance to commence clinical activities. Although we will require additional funds for specific development programs, we believe the current funding go a long way to satisfying our general operations and specific research programs into 2011." The Company completed the placement of a series of debentures to existing investors in the principal amount of $2,103,000, convertible into common stock at $0.10 per share for which the Company was paid $1,752,000. The Company will be required to redeem the debentures monthly commencing in May 2010, in the amount of 14.28% of the initial principal amount of the Notes, in cash or common stock at the Company's option. The investors also received warrants to purchase an aggregate of 14,020,000 shares of common stock at an exercise price of $0.108. Further, the investors are obligated to purchase an additional $2,103,000 principal amount of debentures and 14,020,000 warrants within 90 days, at a purchase price of $1,752,000, subject to customary conditions. The investors also received an Additional Investment Right, which terminates in August 2010, and allows the investors to purchase up to $2,200,000 of principal amount of the Company's convertible notes on the same terms and conditions as the original notes purchased in the offering. If the investors exercise their Additional Investment Right, they will also receive one and one third Class B warrants for each two shares that would be issued if the investors converted the entire portion of the note purchased pursuant to their Additional Investment Right.

The Company also entered into amended agreements with an existing investor. Under the first amended agreement, the Company received gross proceeds of $1,000,000 and issued a secured and collateralized convertible promissory note for $1,200,000. The Company shall pay a one-time interest payment of 10% of the principal of the promissory note which is due on the maturity date of the promissory note, which is in October, 2012. The promissory note is convertible into shares of the Company's Common Stock at a conversion price of the lesser of (i) $.25 per share or (ii) eighty percent of the average of the three lowest trade prices in the 20 trading days prior to the conversion. Under the second amended agreement, the Company received gross proceeds of $1,000,000 and issued a Secured & Collateralized Promissory Note for $1,000,000. The Company shall pay a one-time interest payment of 12% of the principal of the promissory note which is due on the maturity date of the promissory note, which is in October, 2012. The promissory note is secured by $1,000,000 of a money market fund or other assets of the Investor.

The remaining funding is expected to be provided by Optimus Life Sciences Partners, a private investment fund with offices in New York and California, under which Advanced Cell may sell up to $10 million of 10% non-convertible perpetual preferred stock and warrants to purchase up to approximately 119,000,000 shares of common stock, subject to meeting certain conditions. The warrants are exercisable only to the extent the Company elects to put preferred stock to Optimus. Warrants to purchase common stock equal to 135% of the monies funded by Optimus will be exercisable at the market price of the common stock at the time of each funding. The Company agreed to pay Optimus a commitment fee of 5%, payable in cash or registered shares of common stock (priced at 90% of the then current market price), at the option of the Company.

The Company expects to immediately file a registration statement with the SEC in connection with the Optimus transaction, as well as other recent financings and certain other previously issued securities.

Further information on each of the foregoing transactions can be found in the Form 8-K filed today by the Company with the SEC.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements Statements in this news release regarding future ability to draw on the Optimus financing facility, future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the Company's ability to meet all of the conditions to allow it to access the entire amount available under its financing facilities discussed in this press release, limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

The securities described above were sold by the Company in private placements and were not registered under the Securities Act of 1933, as amended (the "Securities Act"). The securities were sold in reliance upon exemptions from the registration requirements of the Securities Act pursuant to Regulation D promulgated under the Securities Act. Therefore, the securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and any applicable state securities laws. This press release does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities.

FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting

ATLANTA, Nov 17, 2009 -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX | Quote | Chart | News | PowerRating) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV. The meeting will only take place if the Company is not satisfied or requires some clarification to the FDA's answers to the questions submitted in the pre-IND package. Following the FDA response to the Pre-IND meeting questions, GeoVax will prepare and submit to the FDA an IND application for the therapeutic trial.

Robert McNally, Ph.D., president and chief executive officer, stated, "In anticipation of a pre-IND meeting in mid December, we have submitted a pre-IND information packet to the FDA. This packet includes rationale and supporting data for each question in the pre-IND package to allow a response from the FDA. The main purpose of the Pre-IND meeting is to ensure the FDA understands the purpose, approach and endpoints for the anticipated Phase 1 therapeutic trial and that we have answers to all of our questions to the FDA prior to filing the actual IND.

"While there are no guarantees of success for our therapeutic IND package, the pre-IND process helps ensure that our IND will adequately address any concerns the FDA may have about the proposed therapeutic trial," Dr. McNally added. "We understand the extreme need for this vaccine and we understand the process necessary to navigate forward." A new IND with the FDA is required since this will be the first time the GeoVax vaccine will be used for a therapeutic application. The Phase 1 therapeutic protocol stresses safety parameters to minimize any risk to the volunteers. The protocol, conceived with collaboration from ARCA (AIDS Research Consortium of Atlanta), has specific objectives to optimize safety while evaluating the ability for the vaccine to elicit protective immune responses in vaccinated participants. The proposed trial is based on the achievement of excellent post-vaccine viral control in animal trials conducted in recently infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University. The proposed human trial follows the precedents set in the preclinical animal trials and is a critical step towards developing a therapeutic vaccine for HIV-1 infected humans.

The IND process is expected to take a number of months to complete. Based on the Company's current progress, commencement of the trial is targeted for early 2010.

HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America, where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

About Standoutstocks.com www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx

CONTACT: Jason A. Hilton, Standout Stocks
Tel: +1 585 729 8809
e-mail: Jason@Newmediaadvisorsllc.com
e-mail: info@standoutstocks.com
WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (ACTC) ACTC. (ACTC) has Short Term PowerRatings at TradingMarkets. Details on (ACTC) Short Term PowerRatings is available at This Link.

For full details on (GOVX) GOVX. (GOVX) has Short Term PowerRatings at TradingMarkets. Details on (GOVX) Short Term PowerRatings is available at This Link.

For full details on (NYMH) NYMH. (NYMH) has Short Term PowerRatings at TradingMarkets. Details on (NYMH) Short Term PowerRatings is available at This Link.

For full details on (HLXW) HLXW. (HLXW) has Short Term PowerRatings at TradingMarkets. Details on (HLXW) Short Term PowerRatings is available at This Link.